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findings: 31 with low-grade dysplasia (low grade), 11 
with high-grade dysplasia (high grade), and 23 with asso-
ciated invasive carcinoma (invasive Ca). Mutations in the 
KRAS or GNAS genes were analyzed by Sanger sequenc-
ing, and methylation status of two discrete regions within 
the EFEMP1 promoter, namely region 1 and region 2, 
was analyzed by bisulfite sequencing and fluorescent 
high-sensitive assay for bisulfite DNA (Hi-SA). Expres-
sion status of EFEMP1 was investigated by immunohis-
tochemistry (IHC).
Results KRAS mutations were detected in 39, 55, and 
70 % of low-grade, high-grade, and invasive Ca, respec-
tively. GNAS mutations were observed in 32, 55, and 
22 % of low-grade, high-grade, and invasive Ca, respec-
tively. The methylation of individual regions (region 1 
or 2) in the EFEMP1 promoter was observed in 84, 91, 
and 87 % of low-grade, high-grade, and invasive Ca, 
respectively. However, simultaneous methylation of both 
regions (extensive methylation) was exclusively detected 
in 35 % of invasive Ca (p = 0.001) and five of eight 
IPMNs (63 %) with extensive methylation, whereas 20 
of 57 (35.1 %) tumors of unmethylation or partial meth-
ylation of the EFEMP1 promoter region showed weak 
staining EFEMP1 in extracellular matrix (p = 0.422). 
In addition, extensive EFEMP1 methylation was par-
ticularly present in malignant tumors without GNAS 
mutations and associated with disease-free survival of 
patients with IPMNs (p < 0.0001).
Conclusions Extensive methylation of the EFEMP1 gene 
promoter can discriminate invasive from benign IPMNs 
with superior accuracy owing to their stepwise accumula-
tion of tumor progression.
Keywords Mucinous neoplasms · Methylation · 
Epigenetics · EFEMP1 · Invasive carcinoma · Dysplasia
Abstract 
Purpose Although limited understanding exists for the 
presence of specific genetic mutations and aberrantly meth-
ylated genes in pancreatobiliary intraductal papillary muci-
nous neoplasms (IPMNs), the fundamental understand-
ing of the dynamics of methylation expansion across CpG 
dinucleotides in specific gene promoters during carcinogen-
esis remains unexplored. Expansion of DNA methylation in 
some gene promoter regions, such as EFEMP1, one of the 
fibulin family, with tumor progression has been reported in 
several malignancies. We hypothesized that DNA hyper-
methylation in EFEMP1 promoter would expand with the 
tumor grade of IPMN.
Methods A sample of 65 IPMNs and 30 normal pan-
creatic tissues was analyzed. IPMNs were divided into 
the following three subsets according to pathological 
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Introduction
Pancreatic intraductal papillary mucinous neoplasms 
(IPMNs) are precursor lesions characterized by an atypi-
cal degree of intraductal proliferation of neoplastic muci-
nous cells arising in the pancreatic duct (Das et al. 2013; 
Matthaei et al. 2012; Tanaka et al. 2012; Wasif et al. 2010). 
Histologically, IPMNs may progress from low-grade to 
high-grade dysplasia and finally to an invasive carcinoma 
(Das et al. 2013; Farrell and Brugge 2002; Salvia et al. 
2004), canonical to the adenoma-carcinoma sequence in 
colorectal cancer and pancreatic ductal adenocarcinoma 
(PDAC) (Wasif et al. 2010). While IPMNs with invasive 
carcinoma have a poor 5-year survival ratio of 33–43 %, 
patients with resected IPMNs without any invasive can-
cer features generally have a better 5-year survival ratio of 
77–94 % (Chari et al. 2002; Das et al. 2013; Farrell and 
Brugge 2002; Maire et al. 2002; Raimondo et al. 2002; 
Sohn et al. 2004), highlighting the importance of efficient 
diagnosis of IPMNs with invasive carcinoma. Therefore, 
preoperative identification of dysplastic IPMNs is chal-
lenging even with a multimodality approach including 
radiographic imaging, endoscopic ultrasound-guided fine-
needle aspiration (EUSFNA), cytological examination, and 
tumor markers (Schoedel et al. 2006). This problem has 
prompted the development of other analytical tools, includ-
ing genomic biomarkers that can predict IPMNs at a high 
risk of developing dysplasia with malignant potential (Sch-
oedel et al. 2006).
Applying molecular techniques to evaluate surgical and 
cytological specimens is evolving in conjunction with our 
understanding of the IPMN molecular makeup (Schoedel 
et al. 2006). Studies aimed at characterizing genetic profiles 
in IPMNs have identified activating mutations of KRAS and 
GNAS oncogenes and inactivating mutations in RNF43, 
CDKN2A/p16, and TP53 tumor suppressor genes (Amato 
et al. 2014; Cooper et al. 2013; Dal Molin et al. 2013; Furu-
kawa et al. 2011; Kanda et al. 2013; Komatsu et al. 2014; 
Schonleben et al. 2007, 2008; Sessa et al. 1994). Collec-
tively, these studies underscored the importance of genetic 
alterations in IPMN progression; however, the prevalence 
of such genetic events generally occurs at lower frequen-
cies than in PDAC (Adsay 2002; Cooper et al. 2013; Kanda 
et al. 2013; Sato and Goggins 2006).
Similar to other cancers, epigenetic alterations, such as 
promoter hypermethylation of tumor suppressor genes, are 
considered a critical process in IPMN development (Sato 
and Goggins 2006). Results suggest a gradual expansion 
of methylation across CpG islands in MGMT, RASSF2, 
and SFRP2 promoters during colorectal cancer progres-
sion and highlighted their potential role as biomarkers for 
diagnosis and disease prediction for specific cancer types 
(Nagasaka et al. 2008, 2009; Takeda et al. 2011). In this 
study, we evaluated the methylation status of the epidermal 
growth factor-containing fibulin-like extracellular matrix 
protein 1 gene (EFEMP1, alternative annotation is FIbu-
lin3), a member of the fibulin family of extracellular matrix 
(ECM) proteins. EFEMP1 is involved in malignant trans-
formation through modulation of cell proliferation, angio-
genesis, and invasion in a tissue-dependent manner (Kob-
ayashi et al. 2007; Sadr-Nabavi et al. 2009; Wang et al. 
2010, 2012; Yang et al. 2013; Yue et al. 2007; Zhu et al. 
2014), and alterations in this gene expression have often 
been linked to aberrant DNA methylation (Nomoto et al. 
2010; Sadr-Nabavi et al. 2009; Wang et al. 2010, 2012; 
Yang et al. 2013; Yue et al. 2007; Zhu et al. 2014). Moreo-
ver, recent studies have reported an association between a 
reduction in protein expression and EFEMP1 methylation 
expansion in breast and lung cancers using immunohisto-
chemistry and sequencing approaches (Chen et al. 2014; 
Sadr-Nabavi et al. 2009). For these reasons, the presence or 
absence of methylation and gradual expansion of specific 
gene promoter methylation may help diagnose and differ-
entiate invasive carcinoma from normal adjacent tissues 
and dysplastic lesions.
To systematically test this hypothesis, we first analyzed 
mutations in the KRAS and GNAS genes to confirm the genetic 
background of IPMNs. Next, to determine whether extensive 
methylation of candidate genes may serve as a predictive alter-
ation for malignant IPMNs, we performed a comprehensive 
investigation of the methylation status of EFEMP1 promoter 
and examined EFEMP1 expression status by IHC.
Materials and methods
Samples and tumor classifications
Nine tissues from non-necrotic areas of PDAC were frozen 
immediately at −80 °C, and DNA was extracted from the 
tissues using QIAamp DNA mini kits (Qiagen, Valencia, 
CA, USA). DNAs of 21 tissues from non-necrotic areas of 
PDAC were macrodissected from formalin-fixed, paraffin-
embedded (FFPE) specimens. DNAs of IPMNs were mac-
rodissected from 65 patients who underwent surgical resec-
tion and who were pathologically diagnosed with IPMNs or 
invasive IPMNs. All samples were collected from the Okay-
ama University Hospital, Okayama, Japan, between Janu-
ary 2001 and December 2012. Institutional review board 
approval was granted by the Ethics Committee of the Okay-
ama University, and written informed consent was obtained 
from all patients to use their tissues for research. The medi-
cal records of the patients were retrospectively explored and 
matched with clinical and pathological data. We defined 
IPMN classification based on the International Consen-
sus Guidelines from 2012 as follows: MD-IPMNs were 
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characterized by segmental or diffused dilation of the main 
pancreatic duct by >5 mm in the absence of other causes 
of obstruction; BD-IPMNs comprised pancreatic cysts of 
>5 mm in diameter communicating with the main pancre-
atic duct; finally, mixed-type lesions were those lesions that 
simultaneously met the criteria of both MD-IPMNs and BD-
IPMNs (Tanaka et al. 2012). In addition, we used a revised 
terminology to classify IPMNs. Formally, IPMNs are clas-
sified according to World Health Organization classification 
based on pathological findings as follows: IPMNs with low-
grade dysplasia, intermediate-grade dysplasia, high-grade 
dysplasia (carcinoma in situ) and associated invasive carci-
noma. Based on the revised classification criteria proposed 
in 2015, IPMNs with intermediate-grade dysplasia are com-
bined together with the ones with low-grade dysplasia and 
are now called low-grade IMPNs. Therefore, we classified 
IPMNs according to this revised nomenclature.
IPMN patients’ characteristics
Using the criteria mentioned above, our sample of 65 IPMNs 
was classified as follows: 31 (48 %), 11 (17 %), and 23 
(35 %) IPMNs were classified as low- or intermediate-grade 
dysplasia (low grade), high-grade dysplasia (high grade), 
and invasive Ca, respectively. To clarify the clinicopathologi-
cal features of IPMNs, statistical analyses were performed 
between low-grade and high-grade and invasive Ca (Supple-
mentary Table 1). Within the group of 23 invasive Ca, only 
one case showed a distant metastasis in the liver at surgical 
resection (and hence classified as stage IV); the remainder of 
the invasive Ca cases was categorized as stage I (10 of 23; 
44 %) and stage II (12 of 23; 52 %, Supplementary Table 2). 
Disease-free survival (DFS) and overall survival (OS) of 
IPMNs were estimated according to their clinicopathological 
characteristics (Supplementary Fig. 1). The median time of 
the follow-up period of 65 IPMNs after surgical resection was 
48 months (range 8–108 months). The lesions categorized as 
invasive Ca were also classified by the tumor node metastasis 
classification system (Adsay et al. 2010; Kim et al. 2008).
Direct sequencing of KRAS and GNAS mutations 
in IPMNS tissues
KRAS mutations in codons 12 and 13 were determined by 
the method previously described (Nagasaka et al. 2008, 
2009; Takeda et al. 2011). GNAS mutations in codon 201 
were analyzed by direct sequencing using GNAS primers 
(Supplementary Fig. 2 and Supplementary Table 3).
Analysis of DNA methylation
DNA was subjected to sodium bisulfite modification 
using the EZ DNA Methylation Kit (ZYMO Research, 
Irvine, CA). As shown in Fig. 1, methylation status of the 
EFEMP1 gene promoter was studied at various regions 
in previous studies (Kobayashi et al. 2007; Nomoto et al. 
2010; Sadr-Nabavi et al. 2009; Wang et al. 2010, 2012; 
Yang et al. 2013; Yue et al. 2007; Zhu et al. 2014). In this 
study, we searched CTCF biding sites by CTCFBSDB 
2.0 (http://insulatordb.uthsc.edu/) in promoter region of 
the EFEMP1 gene and found a CTCF biding site ‘TGA-
CATCTGTTGGG,’ called as the EMBL_M1 motifs 
(Schmidt et al. 2012). CTCF, also known as CCCTC-bind-
ing factor, is a transcription factor involved in many cellu-
lar processes, including transcriptional regulation, insulator 
activity, V(D)J recombination, and regulation of chromatin 
architecture (Chaumeil and Skok 2012; Phillips and Corces 
2009). Interestingly, this biding site was between the two 
regions which were analyzed by previous studies as men-
tioned above. For the reason, we divided the EFEMP1 gene 
promoter into two regions (regions 1 and 2, Fig. 1), which 
were located as dividing line on the CTCF biding site, 
and analyzed by a fluorescence high-sensitive assay (Hi-
SA) using bisulfite-modified DNA template as previously 
described (Nagasaka et al. 2009). The sense and antisense 
nonspecific primers and internal methylation-specific prim-
ers with enhanced sensitivity for polymerase chain reaction 
(PCR) amplification have been described previously (Naga-
saka et al. 2009) and are shown in Supplementary Table 3. 
PCR products digested with HhaI (New England BioLabs, 
Massachusetts, USA) were loaded simultaneously onto 
an ABI 310R or 31000 Genetic Analyzer (Applied Bio-
systems, California, USA). Signals from individual PCR 
products were distinguished by the unique fluorescent PCR 
signal from each target and their fragment length, and the 
data were analyzed using GeneMapper software version 
4.0 (Applied Biosystems, California, USA). In this study, 
the percentages of methylated HhaI sites were calculated 
by determining the ratios between the HhaI-cleaved PCR 
product and the total amount of PCR product in each loci, 
and methylation positivity was defined as a proportion of 
>1.0 % of methylated HhaI sites. Direct sequencing of the 
two regions in the EFEMP1 promoter was performed by 
PCR products obtained from bisulfite DNA extracted from 
normal pancreatic tissues and IPMNs. Primer sequences 
are shown in Supplementary Table 3.
Immunohistochemical analysis
EFEMP1 localization was performed by immunohisto-
chemical (IHC). A sample of 65 IPMNs was available for 
IHC staining for EFEMP1 protein expression analysis. 
Staining was carried out manually with FFPE tissues. Thin 
(5 µm) sections of representative blocks were deparaffi-
nized and dehydrated using gradient solvents. Following 
antigen retrieval in the citrate buffer (pH 6.0), endogenous 
1560 J Cancer Res Clin Oncol (2016) 142:1557–1569
1 3
peroxidase was blocked with 3 % H2O2. Thereafter, slides 
were incubated overnight in the presence of a purified 
mouse anti-human EFEMP1 monoclonal antibody (sc-
33722, Santa Cruz, Dallas, TX, USA; dilution 1:250). Fur-
ther incubation was carried out with a secondary antibody 
and the avidin–biotin–peroxidase complex (Vector Labo-
ratories, Burlingame, CA, USA) and then incubated with 
biotinyl-tyramide followed by streptavidin-peroxidase. 
Diaminobenzidine was used as a chromogen and hematox-
ylin as a nuclear counterstain.
EFEMP1 was detectable in normal pancreatic tissue; 
weak staining was detected in islets of Langerhans, whereas 
intense staining was observed in the peripheral nerve fiber. 
IHC results were interpreted by pathologists blinded to the 
corresponding clinicopathological data. The expression sta-
tus of EFEMP1 was evaluated by an immunoreactive score 
(IRS), which was calculated by scoring of the percentage 
of positive cells and their expression intensities. The per-
centage of positive ECM staining was rated as described 
previously and as follows: 1 = 0–10 %, 2 = 11–50 %, 
3 = 51–80 %, and 4 = 81–100 % (Sadr-Nabavi et al. 
2009). Staining intensity was scored as follows: 1 = weak, 
2 = moderate, and 3 = intensive. All IPMNs were catego-
rized into four subsets by IRS score as follows: 0–1 = no 
staining, 2–3 = weak staining, 4–8 = moderate staining, 
and 9–12 = strong staining (Remmele and Stegner 1987).
Statistical analyses
All statistical analyses were performed using EZR (Saitama 
Medical Center, Jichi Medical University), which is a 
graphical user interface for R (The R Foundation for Statis-
tical Computing, version 2.13.0). First, methylation levels 
were analyzed as continuous variables. Next, the methyla-
tion status was analyzed as a categorical variable (posi-
tive, methylation level >1.0 %; negative, methylation level 
≤1.0 %), as described previously. Each IPMN specimen 
was given a numerical score so as to reflect the number 
of methylated loci. Categorical variables were compared 
by Fisher’s exact test. Differences between continuous 
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Fig. 1  Bisulfite sequencing of the discrete EFEMP1 gene pro-
moter regions. a Schematic representation of the location of discrete 
EFEMP1 gene promoter regions and the result of bisulfite sequenc-
ing. The white and gray boxes denote untranslated and translated 
exon in the EFEMP1 gene, respectively. The red allow indicates 
the location of the EMBL_M1 motifs ‘TGACATCTGTTGGG’, a 
candidate of CTCF biding site. The black arrow indicates the tran-
scriptional starting site. The blue box indicates the regions of which 
methylation status was analyzed by Nomoto et al. (2010). The green 
box indicates the regions of which methylation status was analyzed 
by Yue et al. (2007) and Sadr-Nabavi et al. (2009). Vertical lines 
indicate CpG sites; white circles represent unmethylated CpGs; and 
gray circles represent methylated and unmethylated CpGs observed 
by bisulfite direct sequencing. b Examples of bisulfite sequencing in 
region 1 and 2. Each CpG was categorized as unmethylated or meth-
ylated CpG. TpG denotes the CpG site consisting of unmethylated 
CpG only. C/TpG denotes the CpG site consisting of both methylated 
(CpG) and unmethylated CpGs (TpG)
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variables were determined using the Mann–Whitney U 
test or the Kruskal–Wallis test. Multiple comparisons were 
performed using the Steel–Dwass test. OS was calculated 
from the date of surgical resection to the date of death due 
to IPMNS or last follow-up for censored patients. DFS was 
calculated from the date of surgical resection to the date of 
the first documentation of local, regional, or distant relapse, 
appearance of a second primary lesion by computed tomog-
raphy and/or magnetic resonance imaging routinely per-
formed per 6 months. OS and DFS were univariately esti-
mate with the Kaplan–Meier method. All p values reported 
were calculated by two-sided tests, and values <0.05 were 
considered statistically significant.
Results
KRAS and GNAS mutations in IPMNs
To evaluate the genetic background in our current cohort, 
we analyzed mutations in KRAS and GNAS genes as shown 
in Supplementary Figure 2. KRAS mutations were detected 
in 33 IPMNs (51 %), and the spectrum of relative frequen-
cies of individual mutations was 5 (15 % of KRAS mutants), 
12 (36 %), and 16 (49 %) for G12R, G12D, and G12V 
mutations, respectively (Supplementary Tables 1 and 2). 
Meanwhile, 19 IPMNs (29 %) harbored GNAS mutations, 
and the following mutations were primarily found in codon 
201: R201H, 5 IPMNs (26 %); R201C, 13 IPMNs (68 %); 
and R201S, 1 IPMNs (5 %) (Table 2). One R201S was a 
novel mutation, which had not been previously described 
for IPMNs. KRAS mutation frequency tended to increase 
with IPMN grade: 12 of 31 were low grade (39 %), 6 of 
11 were high grade (55 %), and 16 of 23 were invasive Ca 
(70 %, p = 0.084; low-grade vs. high-grade/invasive Ca). 
In contrast, GNAS mutations were constantly observed, 
with 10 of 32 (32 %) in low-grade and 12 of 33 (36 %) in 
high-grade and invasive Ca. Concurrent KRAS and GNAS 
mutations were observed in 11 IPMNs (17 %), KRAS muta-
tion were present only in 22 IPMNs (34 %), GNAS muta-
tions only in 8 IPMNs (12 %), and wild-type status of both 
genes was observed in 24 IPMNs (37 %, Supplementary 
Fig. 2C).
We assessed DFS and OS according to KRAS or GNAS 
mutation status. Although KRAS mutations were more fre-
quently observed in invasive Ca, there was no difference in 
outcome between KRAS mutants and wild type (Supple-
mentary Fig. 2E and F). In contrast, GNAS mutations were 
less frequently observed in invasive Ca compared with low 
and high grade, and there was no difference in outcome 
between GNAS mutants and wild type (Supplementary 
Fig. 2G and H).
Methylation profiles of EFEMP1 promoter in IPMNs
We investigated the methylation status of discrete regions 
in the EFEMP1 promoter in 65 IPMNs and 30 normal 
pancreatic tissues obtained from PDAC patients. The 
location of the EFEMP1 gene and a panel of representa-
tive bisulfite sequencing and fluorescent Hi-SA results are 
depicted in Figs. 1 and 2a, respectively. Methylation status 
in the discrete regions obtained from fluorescent Hi-SA 
was analyzed as the categorical variable. Figure 2b presents 
methylation frequency in each discrete region according to 
pathological features, and Table 1 presents the correlation 
between the methylation status of EFEMP1 and the clinical 
and pathological features of IPMNs. The region-1 methyla-
tion was frequently observed in invasive Ca (p = 0.0016), 
whereas the region-2 methylation was commonly observed 
in IPMN (>80 % of IPMNs) but less frequently in normal 
pancreatic tissues (<20 %). Another interesting feature of 
IPMNs with extensive EFEMP1 methylation was histo-
logic subtype, in which extensive EFEMP1 methylation 
was frequently observed in pancreatobiliary type lesions (4 
of 6; 67 %, p = 0.027). 
With respect to KRAS/GNAS mutation status, interest-
ingly, IPMNs with methylation of the region-1 never har-
bored GNAS mutations (0 of 10; 0 %, p = 0.028), while 
7 of 10 IPMNs with methylation of the region-1 harbored 
KRAS mutations (70 %). While methylation of the region-2 
promoter was frequently observed (54 of 65 IPMNs 
[83 %]), no associations were observed among the frequen-
cies of region-2 methylation and any of the clinicopatho-
logical factors.
Next, we evaluated correlations between the methylation 
status of EFEMP1 promoter and the clinicopathological 
features of invasive Ca (Supplementary Table 3). However, 
methylation status had no association with any of the fea-
tures explored in invasive Ca.
Finally, we also assessed DFS and OS according to 
methylation status in the discrete EFEMP1 promoter 
regions. As extensive EFEMP1 methylation was a specific 
feature of invasive Ca, IMPNs with extensive EFEMP1 
methylation showed a poor prognosis compared with 
IMPNs without extensive EFEMP1 methylation (Fig. 2c, 
d).
Association of EFEMP1 promoter methylation and 
protein expression
We investigated EFEMP1 protein expression in 65 IPMN 
tissues. Representative examples of IHC staining results are 
shown in Fig. 3a–c. Using these criteria, no IPMNs were 
categorized as having no staining, whereas 25, 38, and 2 
IPMNs were deemed to have weak, moderate, and strong 
1562 J Cancer Res Clin Oncol (2016) 142:1557–1569
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staining, respectively. Although five of eight IPMNs (63 %) 
showed weak staining and extensive methylation of the 
EFEMP1 promoter region, no significant differences in the 
frequencies of EFEMP1 protein expression were observed 
in IPMNs exhibiting partial methylation or non-methyla-
tion in the EFEMP1 promoter (Fig. 3d).
Discussion
We have shown for the first time the biological significance 
of methylation in discrete promoter regions of EFEMP1 
gene in tissue specimens obtained from patients with pan-
creatobiliary IPMNs, playing an important functional role 
in malignant transformation by modulating cell prolifera-
tion, angiogenesis, and invasion in a tissue-dependent con-
text (Kobayashi et al. 2007); it is a common target of pro-
moter hypermethylation in various tumors (Nomoto et al. 
2010; Sadr-Nabavi et al. 2009; Wang et al. 2010, 2012; 
Yang et al. 2013; Yue et al. 2007; Zhu et al. 2014). Aber-
rant hypermethylation of the EFEMP1 promoter region is 
a potential biomarker. Sadr et al. reported an association 
between reduction in protein expression and EFEMP1 
methylation expansion in breast cancer using sequenc-
ing approaches and IHC (Sadr-Nabavi et al. 2009). In this 
study, we also examined the association between EFEMP1 
expression in ECM by IHC and EFEMP1 methylation pro-
files. Unfortunately, although 63 % of IPMNs with exten-
sive methylation of the EFEMP1 promoter region showed 
weak staining in ECM, no significant differences in the fre-
quencies of EFEMP1 protein expression were observed in 
IPMNs exhibiting partial methylation or non-methylation 
in the EFEMP1 promoter.
Considering the importance of EFEMP1, we hypoth-
esized that gradual expansion of methylation across its 
promoter during the development of IPMN serves as a bio-
marker for distinguishing malignant IPMNs from the non-
malignant ones. To systematically test this hypothesis, we 
first analyzed mutations in the KRAS and GNAS oncogenes 
to confirm the genetic background of IPMNs. Usually, 
the methylation pattern in a gene promoter is considered 
either entirely methylated or non-methylated. However, 
as demonstrated by bisulfite sequencing, individual CpG 
residues within the EFEMP1 promoter were not equally 
methylated. In this study, region-2 of the EFEMP1 pro-
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Fig. 2  Methylation analysis of EFEMP1. a Results of EFEMP1 
methylation by fluorescent Hi-SA. Blue arrows represent PCR 
fragments with non-methylation in HhaI sites. Red arrows repre-
sent methylated PCR fragments cleaved by HhaI. b Frequencies of 
EFEMP1 methylation according to pathological findings. Kaplan–
Meier survival curves for disease-free survival (c), excluding a patient 
with remaining cancer at the resected margin, and overall survival (d) 
according to EFEMP1 promoter methylation status
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the aberrant methylation tended to spread from region-2 
toward region-1 with IPMN progression. More importantly, 
none of the normal pancreatic tissues, low- or high-grade 
IMPNs showed extensive methylation in the EFEMP1 pro-
moter. These characteristics of the EFEMP1 methylation 
pattern in IPMN carcinogenesis appeared similar to those 
of MGMT, SFRP2, and RASSF2 in the adenoma-carcinoma 
sequence of colorectal cancer (Nagasaka et al. 2008, 2009; 
Takeda et al. 2011). Therefore, the presence or absence of 
methylation and the gradual expansion of methylation of 
specific gene promoters may help diagnose and differenti-
ate invasive carcinoma from normal adjacent tissues and 
dysplastic lesions. This fundamental concept of stepwise 
expansion of DNA methylation across specific gene pro-
moters during the neoplastic progression of IPMNs remains 
unexplored and is still an active area of investigation.
KRAS and GNAS mutations, the most common genetic 
mutations observed in IPMNs, occurred in the early stages 
of disease progression. KRAS and GNAS mutations were 
also found at codon 12 (a G12D, G12V, or G12R) and codon 
201 (an R201H or R201C), respectively. These genetic fea-
tures are in line with those previously reported in other stud-
ies (Amato et al. 2014; Furukawa et al. 2011; Sadr-Nabavi 
et al. 2009; Wu et al. 2011a, b). This agreement indicates that 
KRAS mutations at codon 12 or GNAS mutations at codon 
201 could play a key role as the driver of carcinogenesis, 
providing a selective advantage in tumor formation associ-
ated with these IPMNs (Parmigiani et al. 2009). However, 
the frequencies of both genetic mutations, especially GNAS 
mutations, were different among genetic mutational analy-
ses. In the current study, GNAS mutations were observed 
with similar frequencies in low-grade and invasive Ca. 
However, Furukawa et al. (2011) reported that GNAS muta-
tions were more common in low-grade lesions. In contrast, 
Amato et al. and other authors showed that GNAS mutation 
frequency tended to increase with tumor progression (Amato 
et al. 2014; Wu et al. 2011a, b). These differences in observa-
tions might partly be due to smaller sample size or variations 
in the detection technologies used in the studies.
To our knowledge, no studies have been published so far 
demonstrating a correlation between genetic and epigenetic 
alterations in IPMNs although several previous reports have 
revealed that there are distinct patterns of genetic mutations 
in IPMN subtypes (Amato et al. 2014; Chadwick et al. 
2009; Cooper et al. 2013; Dal Molin et al. 2013; Fritz et al. 
2009; Komatsu et al. 2014; Mino-Kenudson et al. 2011; 
Mohri et al. 2012). In this study, extensive methylation 
of EFEMP1 was likely to occur in IPMNs without GNAS 
mutations (Table 2). This result might reflect the biological 
behavior of the GNAS gene pathway, which is less aggres-
sive than that of the KRAS gene, and further investigation is 
needed to evaluate the roles of KRAS and GNAS mutations 
in IPMN carcinogenesis.
Our study has several limitations. One is the sample 
size. Another is that, although we examined the correlation 
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Fig. 3  Expression analysis of EFEMP1. IHC staining of EFEMP1 
in intraductal papillary mucinous neoplasms with strong staining (a), 
moderate staining (b), and weak staining (c). Association between 
EFEMP1 methylation status and IHC staining (d). EFEMP1, epider-
mal growth factor-containing fibulin-like extracellular matrix protein 
1; IHC immunohistochemical; NA not available
1566 J Cancer Res Clin Oncol (2016) 142:1557–1569
1 3
Table 2  Methylation status of 
EFEMP1and Genetic profiles of 
KRAS and GNAS in this cohort
Sample no. Gender Age Duct involvement KRAS GNAS EFEMP
Region 1 Region 2
Low grade
14 M 71 MD WT WT U U
44 M 54 Mixed WT WT U U
47 M 58 MD WT WT U U
46 M 63 BD WT R201C U U
7 F 66 BD WT WT U U
22 F 63 Mixed WT WT U M
50 M 68 Mixed WT WT U M
54 F 76 BD WT WT U M
60 M 66 Mixed WT WT U M
65 M 63 MD WT WT U M
39 M 64 BD WT R201C U M
42 M 59 MD G12V WT M U
56 M 65 BD G12V R201C U M
17 F 71 BD WT WT U M
21 M 67 BD WT WT U M
31 M 78 MD WT WT U M
35 F 57 BD WT WT U M
36 F 62 BD WT WT U M
2 M 61 Mixed WT WT U M
58 M 60 BD WT R201H U M
13 F 74 MD G12R WT U M
30 M 73 Mixed G12D WT U M
57 M 74 Mixed G12R WT U M
67 M 81 BD G12D WT U M
55 F 71 MD G12V R201C U M
41 M 50 BD G12D WT U M
1 F 65 Mixed G12V R201H U M
69 M 71 Mixed G12D R201S U M
18 M 68 BD WT R201C U M
25 M 69 Mixed G12D R201C U M
9 M 73 Mixed G12V R201C U M
High grade
12 M 81 MD WT WT U M
16 M 72 MD WT WT U M
33 F 70 Mixed G12D WT U M
43 M 75 Mixed G12V R201H U M
66 M 79 Mixed WT R201C U M
19 F 67 Mixed G12R WT U M
38 M 66 Mixed G12D R201H U U
8 M 73 Mixed WT WT U M
3 M 70 MD G12V WT U M
34 F 59 BD WT WT U M
53 M 72 MD WT R201C U M
Invasive Ca
48 F 66 Mixed WT WT U M
49 M 67 MD WT R201C U U
10 M 73 MD G12V WT M U
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EFEMP promoter and its expression status by IHC, there 
was no strong correlation between them; hence, further 
investigation is needed. Beyond the limitations, we dem-
onstrated that the extensive methylation in the EFEMP1 
promoter could be a useful predictive marker for invasive 
IPMNs and could serve as a possible means to noninva-
sively screen for invasive IPMNs using DNA obtained from 
EUSFNA, pancreatic juice, and fecal samples.
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